Cell therapy biotech Quell adds $156M for alternative to organ transplant meds
Quell Therapeutics’ $156 million Series B round comes as it prepares to advance to a clinical trial testing its lead regulatory T cell therapy candidate […]
Quell Therapeutics’ $156 million Series B round comes as it prepares to advance to a clinical trial testing its lead regulatory T cell therapy candidate […]
Takeda Pharmaceutical won FDA approval for Livtencity, an antiviral developed to treat cytomegalovirus infection in transplant patients. The agency also approved an Aadi Biosciences drug, […]
A Novartis drug intended to prevent organ rejection has failed to beat out the standard of care therapy in a Phase 2 study in kidney […]
That is the title of a recent paper published in the Journal of Medical Economics with Syvart Dennan, Oliver Diaz, Kelly Birch, Jennifer Cai, Jennifer […]
Three biotechs IPOs priced this week while one gene therapy developer postponed its plans. The biggest IPO belongs to Talaris Therapeutics, a company developing a […]
Copyright © 2024 | WordPress Theme by MH Themes